Compare Aegon Ltd. (AEG) vs Revvity Inc (RVTY) Price & Performance

AEG trades at $9.415, down 0.37% on the day, with a bullish technical signal from moving averages. The company reported mixed recent earnings, beating expectations in Q2 and Q3 2025 but missing in Q4. Revenue for 2024 was $19.52 billion, with net income of $688 million. A dividend of $0.25 per share is scheduled for payment in July 2026. The balance sheet shows total assets of $327.39 billion and a declining debt-to-asset ratio, improving from 2.43 in 2020 to 1.46 in 2024.

AEG presents a moderate investment case with a low P/E of 13.54 and P/S of 0.57, suggesting potential undervaluation. Analyst sentiment is mixed with a 27.78% buy rating. Key risks include volatile cash flows and execution of strategic shifts, such as the relocation to the U.S. and partnership developments. The stock's outlook hinges on sustained profitability and successful implementation of corporate simplifications.

RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.

The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.